Full Press Release Details
IDEAYA Announces IND Clearance by U S FDA enabling Phase 1 Initiation for First in Class PARG Development Candidate IDE161.
IDYA
IDEAYA Announces IND Clearance by U S FDA enabling Phase 1 Initiation for First in Class PARG Development Candidate IDE161
Key Takeaway: IDEAYA Announces IND Clearance by U S FDA enabling Phase 1 Initiation for First in Class PARG Development Candidate IDE161
Price reaction · baseline $17.27 (2023-01-06 close) · clean, no other IDYA news in the window
day 0 close · peak
-3.1%
BiopharmaWatch Analysis
From our catalyst data and publicly available data · not financial adviceBest trade, last catalyst
+47%
120-day peak, hindsight
Typical move
5.2%
average across 6 past catalysts
Cash runway
~42 mo
Minimal dilution risk
Lead asset
IDE892
Phase 1 · NSCLC Adenocarcinoma